A detailed history of Temasek Holdings (Private) LTD transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Temasek Holdings (Private) LTD holds 2,388,576 shares of BGNE stock, worth $422 Million. This represents 2.19% of its overall portfolio holdings.

Number of Shares
2,388,576
Holding current value
$422 Million
% of portfolio
2.19%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$143.93 - $224.51 $344 Million - $536 Million
2,388,576 New
2,388,576 $536 Million
Q3 2023

Nov 14, 2023

BUY
$179.87 - $225.13 $1.09 Million - $1.36 Million
6,059 Added 0.2%
3,014,171 $542 Million
Q2 2023

Aug 14, 2023

BUY
$178.3 - $266.78 $7.43 Million - $11.1 Million
41,649 Added 1.4%
3,008,112 $536 Million
Q1 2023

May 15, 2023

SELL
$215.53 - $274.5 $30.9 Million - $39.4 Million
-143,507 Reduced 4.61%
2,966,463 $639 Million
Q3 2022

May 15, 2023

BUY
$131.8 - $202.24 $18.9 Million - $29 Million
143,507 Added 4.84%
3,109,970 $419 Million
Q3 2022

Nov 14, 2022

BUY
$131.8 - $202.24 $18.9 Million - $29 Million
143,507 Added 4.84%
3,109,970 $419 Million
Q1 2022

May 15, 2023

SELL
$146.52 - $269.56 $21 Million - $38.7 Million
-143,507 Reduced 4.61%
2,966,463 $559 Million
Q1 2022

May 16, 2022

BUY
$146.52 - $269.56 $1.33 Million - $2.45 Million
9,100 Added 0.31%
2,966,463 $559 Million
Q4 2021

Feb 14, 2022

BUY
$248.56 - $389.34 $10.7 Million - $16.8 Million
43,050 Added 1.48%
2,957,363 $801 Million
Q3 2021

Nov 15, 2021

BUY
$249.6 - $403.14 $41.5 Million - $67 Million
166,257 Added 6.05%
2,914,313 $1.06 Billion
Q2 2021

Aug 16, 2021

BUY
$292.75 - $367.01 $380,867 - $477,480
1,301 Added 0.05%
2,748,056 $943 Million
Q1 2021

May 17, 2021

BUY
$260.64 - $382.12 $25.3 Million - $37.1 Million
97,136 Added 3.67%
2,746,755 $956 Million
Q2 2020

Aug 14, 2020

BUY
$123.9 - $195.41 $25 Million - $39.5 Million
202,028 Added 8.25%
2,649,619 $499 Million
Q1 2020

May 15, 2020

BUY
$121.84 - $173.19 $21.6 Million - $30.7 Million
177,491 Added 7.82%
2,447,591 $301 Million
Q1 2018

May 15, 2018

BUY
$97.41 - $177.22 $96.4 Million - $175 Million
990,100 Added 77.35%
2,270,100 $381 Million
Q4 2017

Feb 14, 2018

BUY
$79.6 - $114.73 $71.6 Million - $103 Million
900,000 Added 236.84%
1,280,000 $125 Million
Q3 2017

Nov 14, 2017

BUY
$66.19 - $103.46 $25.2 Million - $39.3 Million
380,000
380,000 $39.3 Million

Others Institutions Holding BGNE

About BeiGene, Ltd.


  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $18.3B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Temasek Holdings (Private) LTD Portfolio

Follow Temasek Holdings (Private) LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Temasek Holdings (Private) LTD, based on Form 13F filings with the SEC.

News

Stay updated on Temasek Holdings (Private) LTD with notifications on news.